MedTrace Logo

TRUST-ACE - Anticancer-treatment Cardiotoxicity Identification by Echocardiography

NCT06310330 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 250

Last updated 2025-06-06

No results posted yet for this study

Summary

TRUST-ACE will compare a simplified echocardiographic protocol focusing on ventricular function with the guideline recommended comprehensive echocardiographic examination using a randomised design in follow-up of breast-cancer patients with respect to identification of cancer treatment related cardiac dysfunction (CTRCD).

Secondly, the study will evaluate whether novel tools used to improve standardization of recordings as well as automated measurements of central measurements, e.g. ejection fraction (EF) and global longitudinal strain (GLS) can improve the precision of echocardiography in daily clinical practice.

Conditions

  • Breast Neoplasm Malignant Primary

Interventions

DIAGNOSTIC_TEST

Comprehensive echocardiographic follow-up

Comprehensive echocardiographic follow-up for identification of CRTCD in breast cancer patients

DIAGNOSTIC_TEST

Simplified echocardiographic follow-up

Simplified echocardiographic follow-up for identification of CRTCD in breast cancer patients

Sponsors & Collaborators

  • St. Olavs Hospital

    collaborator OTHER

  • Norwegian University of Science and Technology

    lead OTHER

Principal Investigators

  • Espen Holte, MD, PhD · St. Olavs Hospital

Study Design

Allocation
RANDOMIZED
Purpose
DIAGNOSTIC
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-03-08
Primary Completion
2026-12-31
Completion
2026-12-31

Countries

  • Norway

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06310330 on ClinicalTrials.gov